Brown, Patrick A. http://orcid.org/0000-0002-8653-1069
Kairalla, John A.
Hilden, Joanne M.
Dreyer, ZoAnn E.
Carroll, Andrew J.
Heerema, Nyla A.
Wang, Cindy
Devidas, Meenakshi
Gore, Lia
Salzer, Wanda L.
Winick, Naomi J. http://orcid.org/0000-0002-6636-3870
Carroll, William L.
Raetz, Elizabeth A.
Borowitz, Michael J.
Small, Donald
Loh, Mignon L.
Hunger, Stephen P. http://orcid.org/0000-0002-5492-3957
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K23 CA111728, U10 CA098543, CA098413, CA180886, CA180899)
Damon Runyon Cancer Research Foundation (CIA 30-06)
Leukemia and Lymphoma Society (SCOR 7327-07, LLS Scholar 2365-12)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
St. Baldrick’s Foundation
Article History
Received: 9 November 2020
Revised: 11 January 2021
Accepted: 29 January 2021
First Online: 23 February 2021
Change Date: 12 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01245-x
Compliance with ethical standards
:
: The authors report the following potential conflicts of interest: PAB: Scientific Advisory Committees for Novartis, Servier, Jazz, and Janssen. LG: Consultancy for Amgen, Novartis, Roche/Genentech; Equity Ownership for Amgen, Anchiano, Blueprint Medicines, Celgene, Clovis, Mirati, Sanofi Paris; Honoraria for Amgen, Roche/Genentech; Scientific Advisory Committee for Amgen; Data Safety and Monitoring Committee member for Novartis and Celgene. EAR: Research Funding from Pfizer; Data Safety and Monitoring Committee member for Celgene. MJB: Honoraria from Beckman Coulter. MLL: Scientific Advisory Committee for Medisix Therapeutics. SPH: Consultancy for Amgen, Bristol Myers Squibb,, and Novartis; Equity Ownership for Amgen; Honoraria for Jazz.